GoldPorp Pharma Limited

Anti-cancer gold compounds have been actively studied in the pursuit of new metal-based anticancer therapeutics due to their much higher in vitro and in vivo cytotoxicity and anti-proliferative activities compared to the current platinum chemotherapy used clinically. Prof. Chi-Ming CHE’s research team at the University of Hong Kong has discovered and developed novel gold compounds displaying promising anti-tumor activity towards a broad spectrum of metastatic cancers. These proprietary gold compounds against multiple protein targets provide much better efficacy than cisplatin and carboplatin used for the treatment of advanced metastatic cancer:

• Proven to be effective against various a broad spectrum of cancers in multiple animal models, including the orthotropic ones
• Superior to the clinically used chemotherapy in cancer patient-derived organoids
• Effective against tumors such as nasopharyngeal carcinoma, liver cancer and pancreatic cancers that have no effective chemotherapy
• Effective toward drug-resistant cancer
• Inhibit metastasis and angiogenesis
• Eliminate cancer stem cells
• Binding to multiple oncogenic molecular targets that are responsible for the proliferation, invasion and migration of cancer cells with high affinity at sub-micro-molar concentrations.

Prof. Che’s team has developed new proprietary anti-cancer platinum compounds with similar efficacy to cisplatin but comparable safety profile as carboplatin. The direct molecular targets of these new anti-cancer platinum compounds have been identified and will be developed to replace cisplatin or carboplatin in the treatment of Stage IV Metastatic Cancers, either as a therapy alone or in combination with immunotherapy.